Renal formulas pretreated with medications alters the nutrient profile

[1]  F. Schaefer,et al.  Optimal care of the infant, child, and adolescent on dialysis: 2014 update. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Navarro-Alarcón,et al.  Serum Zn Levels and Cu/Zn Ratios Worsen in Hemodialysis Patients, Implying Increased Cardiovascular Risk: A 2-Year Longitudinal Study , 2014, Biological Trace Element Research.

[3]  G. Filler,et al.  Trace elements in dialysis , 2014, Pediatric Nephrology.

[4]  J. Flynn,et al.  Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency. , 2013, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[5]  L. Monnens,et al.  Pre-treatment of Dairy and Breast Milk with Sevelamer Hydrochloride and Sevelamer Carbonate to Reduce Phosphate , 2013, Peritoneal Dialysis International.

[6]  K. Wesseling-Perry,et al.  Bone disease in pediatric chronic kidney disease , 2013, Pediatric Nephrology.

[7]  R. Vaillancourt,et al.  Pretreatment of Infant Formula with Sodium Polystyrene Sulfonate , 2013, Pediatric Drugs.

[8]  P. Brenchley,et al.  Pharmacology, efficacy and safety of oral phosphate binders , 2011, Nature Reviews Nephrology.

[9]  J. Roozbeh,et al.  Comment on: Does Zinc Supplementation Affect Inflammatory Markers in Hemodialysis Patients? , 2011, Renal failure.

[10]  C. Exley,et al.  There is (still) too much aluminium in infant formulas , 2010, BMC pediatrics.

[11]  G. Filler,et al.  Picture of the month: severe zinc deficiency in infancy (acrodermatitis enteropathica-like picture). , 2009, Archives of Pediatrics & Adolescent Medicine.

[12]  G. Filler,et al.  Prevalence of complications in children with chronic kidney disease according to KDOQI. , 2006, Kidney international.

[13]  N D Priest,et al.  The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. , 2004, Journal of environmental monitoring : JEM.

[14]  P. Grimm,et al.  Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer , 2004, Pediatric Nephrology.

[15]  G. Beilman,et al.  Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis. , 2004, JPEN. Journal of parenteral and enteral nutrition.

[16]  T. Bunchman,et al.  Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake , 2004, Pediatric Nephrology.

[17]  R. Kleinman,et al.  Pediatric Nutrition Handbook , 2003 .

[18]  H. Sollinger,et al.  Long-term outcomes in pediatric renal transplant recipients who survive into adulthood , 2003, Transplantation.

[19]  P. Grimm,et al.  Mycobacterial peritonitis in pediatric peritoneal dialysis patients , 2003, Pediatric Nephrology.

[20]  J. Cannata-Andía.  Reconsidering the Importance of Long‐Term Low‐Level Aluminum Exposure in Renal Failure Patients , 2001, Seminars in dialysis.

[21]  S. Mukhopadhyay,et al.  Mineral content of infant formula after treatment with sodium polystyrene sulfonate or calcium polystyrene sulfonate. , 1998, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[22]  N. Bishop,et al.  Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. , 1997, The New England journal of medicine.

[23]  L. Bonnet,et al.  [Effect of ion exchange resins on the composition of milk]. , 1997, Nephrologie.

[24]  W. C. Starbuck.  Reduction of potassium and calcium in milk by sodium sulfonated polystyrene resins. , 1972, Kidney international.

[25]  G. V. VAN GOIDSENHOVEN,et al.  The effect of prolonged administration of large doses of sodium bicarbonate in man. , 1954, Clinical science.